Gastrointestinal Cancer | Specialty

Managing BCR-ABL Inhibitor Associated Skin Rash

October 27th 2013

Managing Angiogenesis Inhibitor Related Skin Toxicity

October 27th 2013

Anticipatory Coping in Patients Treated With EGFR Inhibitors

October 27th 2013

Managing EGFR Inhibitor Associated Skin Toxicity

October 27th 2013

FDA Grants Ramucirumab Priority Review for Advanced Gastric Cancer

October 23rd 2013

The FDA has assigned a priority review designation to ramucirumab as a second-line treatment for patients with advanced gastric cancer.

Dr. Peeters on the Utility of Aflibercept in CRC

October 22nd 2013

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the utility of aflibercept in patients with advanced colorectal cancer.

Physical Activity May Reduce the Risk of Esophageal Cancer

October 18th 2013

A meta-analysis of nearly 2000 patients has shown that physical activity may substantially reduce the risk of developing esophageal cancer, especially esophageal adenocarcinoma.

Dr. Tabernero on New Characterizations in CRC

October 18th 2013

Josep Tabernero, MD, PhD, of Vall d'Hebron University Hospital, Barcelona, discusses new characterizations of colorectal cancer.

High Bile VEGF Levels Suggest Pancreatic Cancer

October 16th 2013

A VEGF level greater than 0.5 ng/mL in bile aspirated from the pancreas was 93% effective at identifying pancreatic cancer in patients with biliary stricture

Dr. Venook on the Need for Collaboration in Research

October 14th 2013

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses the need for collaboration in cancer research.

Dr. Ruff on Aflibercept in Elderly Patients With CRC

October 9th 2013

Paul Ruff, MD, director of Medical Oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses treating elderly patients with colorectal cancer with aflibercept.

Matching Ostomy Pouching Systems to Patient Need

October 7th 2013

The American Cancer Society estimates that in 2013, 142,820 individuals in the United States will be diagnosed with colorectal cancer and 72,570 with bladder cancer

Dr. Ruff on Prior Bevacizumab in the VELOUR Trial

October 4th 2013

Paul Ruff, MD, director of medical oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the analysis of prior bevacizumab in the VELOUR trial in patients with metastatic colorectal cancer.

Dr. Yoshino on U3-1565 and TAS-102 in Colorectal Cancer

October 2nd 2013

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses U3-1565 and TAS-102, two agents used to treat colorectal cancer.

Survival Benefit Observed With Cetuximab in RAS Wild-Type Colorectal Cancer

September 30th 2013

Cetuximab plus FOLFIRI may offer a survival advantage over FOLFIRI plus bevacizumab in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer who do not have RAS mutations.

OS Comparable for Panitumumab and Cetuximab in KRAS Wild-Type mCRC

September 29th 2013

Panitumumab proved noninferior to cetuximab in extending overall survival in patients with chemorefractory KRAS wild-type metastatic colorectal cancer.

Personalized Medicine in Colorectal Cancer

September 29th 2013

Novel Therapies in Development for mCRC

September 29th 2013

Second-Line and Salvage Treatment of mCRC

September 29th 2013

Antiangiogenic Therapy in Metastatic Colorectal Cancer

September 29th 2013